Navigation Links
Watson Reaches Settlement with Teva Over Seasonale(R)
Date:5/7/2010

MORRISTOWN, N.J., May 7 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary, Watson Laboratories, Inc. has reached a settlement with Teva Women's Health, Inc. on outstanding patent litigation related to Teva's Seasonale® (levonorgestrel and ethinyl estradiol tablets USP, 0.15 mg/0.03 mg) product.

On December 13, 2007, Teva filed a patent infringement lawsuit against Watson in the United States District Court for the District of New Jersey involving Watson's Quasense® product, which is a generic equivalent of Teva's Seasonale®.  Under terms of the settlement agreement, Teva has granted Watson a fully paid-up license to the U.S. patents covering Seasonale® and Watson will continue marketing its generic equivalent product Quasense® (levonorgestrel and ethinyl estradiol tablets USP, 0.15 mg/0.03 mg).  Watson further admits that the licensed patents are valid and enforceable.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is a leading global specialty pharmaceutical company.  The Company is engaged in the development and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health.  Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement

Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release.  It is important to note that Watson's goals and expectations are not predictions of actual performance.  Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business.  These factors include, among others, the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson and its third party manufacturers' facilities, products and/or businesses; changes in the laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's annual report for the year ended December 31,2009.  Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.

(Logo:  http://www.newscom.com/cgi-bin/prnh/20100121/LA41294LOGO )


'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Watson Confirms EVISTA(R) Patent Challenge
2. Watson Pharmaceuticals to Webcast Annual Meeting of Stockholders on May 7th
3. Watson To Present at Bank Of America/Merrill Lynch 2010 Healthcare Conference
4. Watson Confirms Trilipix(R) Patent Challenge
5. Watson Confirms Rapamune(R) Patent Challenge
6. Watson Confirms Cenestin(R) Patent Challenge
7. Watson Says Appeals Court Affirms Concerta(R) Patent Invalid
8. Watson to Present at Barclays 2010 Global Healthcare Conference
9. Watson Receives FDA Approval for Generic Cardizem(R) LA
10. FDA Approves Watsons TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer
11. Watson Announces Actos(R) Patent Challenge Settlement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... Feb 21, 2017 Research and Markets has ... & Trends - Industry Forecast to 2025" report to their ... The Global ... around 12.3% over the next decade to reach approximately $4.5 billion ... estimates and forecasts for all the given segments on global as ...
(Date:2/21/2017)... Feb. 21, 2017 Centurion Medical Products, ... patient care, is making a major stride in ... of its IRIG-8™Wound Irrigation System . ... quickly deliver copious volumes of irrigation solution to ... is a significant improvement to the traditional syringe ...
(Date:2/21/2017)... Research and Markets has announced the addition of ... Report" report to their offering. ... The report provides separate comprehensive analytics for the US, ... , Asia-Pacific , Latin America ... the period 2015 through 2022. Also, a six-year historic analysis is provided ...
Breaking Medicine Technology:
(Date:2/22/2017)... ... February 22, 2017 , ... Apptricity® Corporation, a ... and spend management, today announced that Keppel Corporation has selected Apptricity Travel and ... , “We are excited to announce the partnership between Keppel and Apptricity ...
(Date:2/21/2017)... ... 21, 2017 , ... Hanna Boys Center http://www.hannacenter.org ... the keynote speaker at its second Professional Networking Breakfast on March 9, 2017. ... comprehensive strategies to create and expand opportunities for boys and young men of ...
(Date:2/21/2017)... ... ... Support of value-based care models requires collaboration across all facets of the ... Fogo Data Centers announces the launch of the Fogo Partner Community™. , At Fogo, ... which all systems work well, work together, and work together well. In healthcare, ...
(Date:2/21/2017)... ... February 21, 2017 , ... HIMSS is ... connected care demonstration spanned multiple health information systems including OpenEMR, EMRDirect, and ... providers have no Health Information Exchange outside of faxing. Medal’s innovative technology “meets ...
(Date:2/20/2017)... , ... February 20, 2017 , ... ... the rate at which women are called back for additional examinations without sacrificing ... Radiology . , In 2011, the U.S. Food and Drug Administration approved digital ...
Breaking Medicine News(10 mins):